ClinicalTrials HQ

A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis

A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis

Recruiting · NCT07725939 · Registry updated 2026-10-09
Ask about research services

Clinical trials

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic BronchitisChronic Disease, Disease Attributes, Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bronchial disorder, bronchitis, chronic bronchitis, chronic obstructive pulmonary disease, lung disorder, obstructive lung disease, respiratory system disorder, respiratory tract infectious disorderRecruitingPhase 22026-10-09NCT07725939

1 results · Page 1 of 1

Organizations

Swipe the table sideways for more columns.

OrganizationsLinked trials
UCB Biopharma SRL30

13 results · Page 1 of 1

Research sites

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Copd01 20001BeijingChina1
Copd01 20002NanchangChina1
Copd01 20003HangzhouChina1
Copd01 20004ChengduChina1
Copd01 20005HangzhouChina1
Copd01 20012ShijiazhuangChina1
Copd01 50001BoerneUnited States1
Copd01 50002DuBoisUnited States1
Copd01 50003ColumbusUnited States1
Copd01 50005TomballUnited States1
Copd01 50008RinconUnited States1
Copd01 50011MiamiUnited States1
Copd01 50013SeattleUnited States1